(Albany, US) DelveInsight has launched a new report on ‘Epidermolysis Bullosa (EB)-Market Insights, Epidemiology, and Market Forecast–2030’.
DelveInsight’s ‘Epidermolysis Bullosa (EB)-Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the EB, historical and forecasted epidemiology as well as the EB market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Epidermolysis Bullosa Key Findings
- According to the publisher's, the total prevalent population of EB in seven major markets ranges was 41,509 in 2017.
- The total diagnosed prevalent cases of EB in the 7MM was 39,433 in 2017.
- In 2017, there were 26,104 prevalent cases of EB in the United States. In the same years, there were a total of 24,799 diagnosed prevalent cases of EB in the United States.
- Epidermolysis Bullosa is of several types, and three major types of Epidermolysis bullosa includes Epidermolysis bullosa simplex (EBS), junctional EB (JEB), and dystrophic EB (DEB). Assessments as perthe publisher's analysts show that the majority of cases of EB are EBS in the United States. In 2017, there were 14,879 cases of EBS, 1,240 cases of JEB, and 8,680 cases of DEB in the United States. DEB is further divided as recessive and dominant.
- Out of 8,680 cases of DEB in the United States in 2017, 4,554 cases were dominant DEB and 4,126 cases were recessive DEB.
- Among the European countries, the United Kingdom had the highest prevalent population of EB with 5,037 cases, followed by Germany which had a prevalent population of 4,919 in 2017. On the other hand, Spain had the lowest prevalent population of 928 in 2017.
View Report: https://www.delveinsight.com/report-store/epidermolysis-bullosa-market
Request for free sample report: https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market
Epidermolysis Bullosa (EB) Emerging Drugs
Oleogel-S10 (AP-101): Amryt Pharma
Oleogel-S10 (AP-101) is a topical product that is being developed for the treatment of EB. It incorporates a betulin-based active ingredient formulated with sunflower oil. AP-101 acts by promoting the differentiation and migration of keratinocytes (skin cells with wound repair capabilities) as well as transiently increasing the level of proinflammatory mediators (which also promote healing).
AP101 has already received marketing approval for the treatment of partial-thickness wounds (PTWs) in adults from the European Commission in January 2016 under the brand name Episalvan. The company is also developing AP103, a potential treatment for patients with RDEB. Oleogel-S10 is currently in phase III clinical trial and recently reported positive unblinded interim efficacy and safety analyses.
EB-101: Abeona Therapeutics
EB-101 (LZRSE-Col7A1) is an autologous, ex-vivo gene therapy in which the COL7A1 gene is inserted into a patient's skin cells (keratinocytes) for the treatment of the underlying disease in recessive dystrophic epidermolysis bullosa (RDEB). The patient's cell is genetically engineered in the lab to express a missing protein called type VII collagen and then these corrected cells will be transplanted back to the patient. These cells should then make type VII collagen. The process of adding inserting the correct type VII collagen gene into cells is called gene transfer. Post this process i.e. gene transfer the engineered cells are grown in culture into a sheet of cells that look like a plastic film. This sheet is then grafted to wounds.
The company has evaluated the safety of EB-101 in phase I/II trial in which product has shown significant results, wound treated with EB-101 were significantly healed >50% for more than two years post-administration.
CCP-020 (Diacerein 1% Ointment): Castle Creek Pharmaceuticals
CCP-020 (Diacerein 1% Ointment) is a topical ointment that is being developed by Castle Creek Pharmaceuticals for the treatment of EBS. The drug is engineered to potentially block the activity of interleukin-1? (IL-1?), a pro-inflammatory cytokine that is involved in the inflammatory signaling pathway associated with EBS. Blocking of IL-1? reduces the auto-inflammatory effects in the skin of patients with EBS and strengthen epidermal tissue and support healing.
Diacerein is a commercially available medicine used to treat osteoarthritis. Its therapeutic potential in treating blistering in patients with epidermolysis bullosa simplex was initially discovered by a team of researchers at the EB House Austria, University Clinic for Dermatology at the Paracelsus Medical University (PMU). Diacerein is commonly marketed as tablets but for EBS researchers have developed an ointment with 1% of diacerein. Presently Castle Creek is developing CCP-020 is in the phase II stage of development. Earlier a phase II trial of CCP-020 for EBS got terminated because an independent data monitoring committee suggested that the study will not meet statistical objectives.
View Report: https://www.delveinsight.com/report-store/epidermolysis-bullosa-market
Request for free sample report: https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market
- Amryt Pharma
- Abeona Therapeutics
- Castle Creek Pharmaceuticals
- RegeneRx
- Krystal Biotech
- Fibrocell Technologies/Castle Creek Pharmaceuticals
- RHEACELL GmbH
- Holostem Terapie Avanzate
- StemRim/Shionogi
- Phoenix Tissue Repair (BridgeBio Pharma, Inc)
- Menlo Therapeutics
- JCR Pharmaceuticals
- Amicus Therapeutics
View Report: https://www.delveinsight.com/report-store/epidermolysis-bullosa-market
Request for free sample report: https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market
- Key Insights
- Executive Summary of Epidermolysis Bullosa (EB)
- Epidermolysis Bullosa (EB) Market Overview at a Glance
3.1. Market Share (%) Distribution of Epidermolysis Bullosa (EB) in 2017
3.2. Market Share (%) Distribution of Epidermolysis Bullosa (EB) in 2030
- Epidermolysis Bullosa (EB): Disease Background and Overview
4.1. Introduction
4.2. Causes of Epidermolysis Bullosa
4.3. Signs and Symptoms of Epidermolysis Bullosa
4.4. Classification of Epidermolysis Bullosa
4.5. Pathophysiology of Epidermolysis Bullosa
4.6. Genetic Bases of Epidermolysis Bullosa
4.7. Diagnosis of Epidermolysis Bullosa
4.7.1. Diagnostic Guidelines
- Case Reports
5.1. Dystrophic Epidermolysis Bullosa in Pregnancy: A Case Report of the Autosomal Dominant Subtype and Review of the Literature
5.2. Managing pain in children with epidermolysis bullosa
5.3. Epidermolysis bullosa: a case report
5.4. Newborn Infant with Epidermolysis Bullosa and Ankyloglossia
- Epidemiology and Patient Population
6.1. Key Findings
6.2. Epidemiology Methodology
6.3. 7MM Total Prevalent Patient Population of Epidermolysis Bullosa
6.4. 7MM Diagnosed Prevalent Patient Population of Epidermolysis Bullosa
6.5. 7MM Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa
- Country Wise-Epidemiology of Epidermolysis Bullosa
7.1. United States Epidemiology
7.1.1. Assumptions and Rationale
7.1.2. Total Prevalent Cases of Epidermolysis Bullosa in the United States
7.1.3. Diagnosed Prevalence of Epidermolysis Bullosa in the United States
7.1.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United States
7.2. EU5 Epidemiology
7.3. Japan Epidemiology
- Treatment and Management of Epidermolysis Bullosa (EB)
8.1. Skin and Wound Management
8.2. General Management Principles
8.3. Special Considerations
8.4. Management of Chronic wounds in EB
8.5. Pain care for patients with epidermolysis bullosa: best care practice guidelines
- Unmet Needs
- Emerging Drugs
10.1. Key Cross Competition
10.2. Oleogel-S10 (AP-101): Amryt Pharma
10.2.1. Product Description
10.2.2. Other Development Activities
10.2.3. Clinical Development
10.2.4. Clinical Trials Information
10.2.5. Safety and Efficacy
10.2.6. Product Profile
10.3. EB-101: Abeona Therapeutics
10.4. CCP-020 (Diacerein 1% Ointment): Castle Creek Pharmaceuticals
10.5. RGN-137: RegeneRx
10.6. B-VEC (KB103, Beremagene Geperpavec): Krystal Biotech
10.7. FCX-007: Fibrocell Technologies/Castle Creek Pharmaceuticals
10.8. Allo-APZ2-EB: RHEACELL GmbH
10.9. COL7 and LAMB3 gene therapy: Holostem Terapie Avanzate
10.10. KOI2 (Redasemtide/HMGB1 Peptides): StemRim/Shionogi
10.11. PTR-01 (BBP-589): Phoenix Tissue Repair (BridgeBio Pharma, Inc)
10.12. Serlopitant (VPD-737): Menlo Therapeutics
- Failed Therapies for Epidermolysis Bullosa (EB)
11.1. JR-031: JCR Pharmaceuticals
11.1.1. Product Description
11.1.2. Other Development Activities
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Product Profile
11.2. Allantoin (Zorblisa): Amicus Therapeutics
- Epidermolysis Bullosa: Seven Major Market Analysis
12.1. Key Findings
12.2. Market Methodology
12.3. Attribute Analysis
12.4. Market Size of Epidermolysis Bullosa in the 7MM
12.5. Market Size of Epidermolysis Bullosa by Therapies in the 7MM
- Market Outlook: The United States
13.1. United States Market Size
13.1.1. The Total Market Size of Epidermolysis Bullosa
13.1.2. Market Size of Epidermolysis Bullosa by Therapies in the United States
- Market Outlook: Europe
- Market Outlook: Japan
- Market Drivers
- Market Barriers
- SWOT Analysis
- Reimbursement and Market Access
- Recognized Establishments
- Appendix
View Report: https://www.delveinsight.com/report-store/epidermolysis-bullosa-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: [email protected]
Phone: +19193216187
City: Albany
State: New York
Country: United States
Website:https://www.delveinsight.com/
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.
Click here to know more on Non-Small Cell Lung Cancer pipeline NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many othersKey Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.Market DriverMarket Barrier The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.Detailed Non-Small Cell Lung Cancer market size by therapies, covering the United States, EU5 and Japan from 2017-2030.Reimbursement scenario and Key Opinion Leader Views Table of ContentsKey InsightsExecutive Summary of NSCLCSWOT Analysis of NSCLCNSCLC: Market Overview at a Glance4.1.
Total Market size of NSCLC in JapanALK-Mutation—Market Size21.1.
Report MethodologyDelveInsight CapabilitiesDisclaimerAbout DelveInsight Request a Webex Demo to get a walk-through of the report: https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-marketRelated Reports:Non-Small Cell Lung Cancer Epidemiology Forecast to 2030Non-Small Cell Lung Cancer Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020Non-Small Cell Lung Cancer Pipeline Insights, 2020About DelveInsightDelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment.
Undifferentiated Marketing is a market coverage strategy whereby differences within a market are ignoredUndifferentiated marketing is market targeting where you pursue the entire market, rather than specific segments
Global Gluten-Free Products Market Strategic Assessment and Forecast 2022-2031Market.us published new study/research report titled “Global Gluten-Free Products Market 2021 Research Report Analysis and Forecast: 2022- 2031” predicts steady growth till 2031 by top Kay Players (Boulder Brands, DR. SCH?R AG/SPA, ENJOY LIFE NATURAL), Types (Bakery Products, Pizzas & Pastas, Cereals & Snacks, Savories), and by applications (Conventional Stores, Hotels & Restaurants, Educational Institutions, Hospitals & Drug Stores, Specialty Services).This research report presents a top to bottom analysis of the Gluten-Free Products industry including enabling market drivers, Porter’s five forces, SWOT analysis, Market Segments, Market Dynamics, Market Size, Supply & Demand, Current Trends/Issues/Challenges, standardization, technologies, recent trends, operator case studies, deployment models, opportunities, future roadmap, value chain analysis and techniques for the new entrants within the world Gluten-Free Products Market over the period of 2022- 2031.Request For Free Sample PDF Copy Of Gluten-Free Products Market Report @ https://chemicalmarketreports.com/report/global-gluten-free-products-market/#requestForSampleGlobal Gluten-Free Products Market Segmented By Top Key Players, Applications, & Types with (sales revenue, price, gross margin, main products):Key Players: This report bases on top creators(Companies) in the global market, with creation, esteem, pay and market share for each maker, coveringBoulder Brands, DR. SCH?R AG/SPA, ENJOY LIFE NATURAL, General Mills, Inc, The Hain Celestial Group, Kraft Heinz, HERO GROUP AG, KELKIN LTD, NQPC, RAISIO PLC, Kelloggs Company, Big Oz Industries, Dominos PizzaThe Gluten-Free Products industry factual reviewing report essentially centers around the business in a world Gluten-Free Products market.
The exploration ponders additionally incorporates bits of knowledge into the key market slants, a point by point examination of the changing focused scene, and income estimates for each portion and sub-fragment.Types: In view of thing(Type), this report demonstrates the creation, salary, esteem, market offer an advancement rate of every kind, in a general sense split intoBakery ProductsPizzas & PastasCereals & SnacksSavoriesApplications: By Application, the market can be part of:Conventional StoresHotels & RestaurantsEducational InstitutionsHospitals & Drug StoresSpecialty ServicesDo You Have Any Query?
Inquire More For Discount OR Report Customization: https://chemicalmarketreports.com/report/global-gluten-free-products-market/#inquiryReasons to Purchase this Report Analyzing the outlook of the market with the current patterns and Porter’s five powers analysisThe market improvement primarily considers the segments which are inducing the present market situation alongside the development chances of the market in the years to comeMarket segment interpretation together with qualitative and quantitative study including the impact of commercial and non-commercial aspectGlobal and Regional level investigation incorporating the request and supply powers that are affecting the development of the marketThe far-reaching investigation of the market in light of advancement openings, Threats, development restricting variables and possibility of speculation will gauge the market development.The investigation of rising Gluten-Free Products market fragments and the current market sections will help the readers in arranging the business methodologies.Comprehensive company profiles covering the product offerings, Financial related data, recent developments, SWOT(strengths, Weaknesses, Opportunities, and Threats) analysis related to business competition or project planning and techniques utilized by the real market playersGet Instant access or to Buy This Premium Gluten-Free Products market Report: https://chemicalmarketreports.com/purchase-report/?reportId=138609/What This Research Report Offers: Global Gluten-Free Products Market share evaluations for the provincial level fragments.Market share investigation of the best Market players.Vital proposals for the new players.Market estimates for at least years of all the given fragments, subsections, and the local markets.Market Trends (Drivers, Opportunities, Threats, Constraints, Investment Opportunities, Challenges, and proposals).Vital necessities in key business segments in light of the Global Gluten-Free Products Market investigation.Industry profiling with a point by point techniques, financials, and current advancements.Initially, Global Gluten-Free Products Market 2021-2031, has been readied in view of a degree of market investigation with commitments from industry experts.
The players in the market encounter concerning premium and supply have been distinguished in the report.
The exploration Refers to information from the previous year 2015 to 2020, the base year 2021 and gauge year until the point when 2031 that makes the report an essential asset that will help industry item chiefs, experts, investigators, officials, marketing, deals, and other individuals searching for entering market Research data in promptly open records.At last, It breaks down the business through an examination of the business chain, industry game plans, and plans, and inside and out examination explore the Products in the market, their gathering chain, cost structure, and so on.Browse Detailed TOC, Tables, Figures, Charts and Companies Here @ https://chemicalmarketreports.com/report/global-gluten-free-products-market/#tocTOC Of Gluten-Free Products Market: Chapter 1: Describes the industry overview/summary/review, market segment, and cost analysis.Chapter 2: Deals with industry environment, industry chain structure, industry overall, industry & investment analysis, manufacturing cost structure, raw material and suppliers, manufacturing process.
this consists of policy, economics, sociology, and technology.Chapter 3: Gluten-Free Products Market by Type (Bakery Products, Pizzas & Pastas, Cereals & Snacks, Savories), Market Size, Market forecast 2022-2031.Chapter 4: Includes major Players list and their business profile, sales data.Chapter 5: Describes the marketplace industry competition.
The Spirulina Market is expected to grow at a CAGR of 10.3% from 2020-2030, according to a new research report by Next Move Strategy ConsultingSpirulina is a blue green algae with high nutrient content, usually consumed by human & animals.
It is also used as a complementary diet ingredient in aquaculture & poultry feeds owing to the presence of high protein & vitamin content.According to the report, growth in health consciousness among people and the rising demand for dietary supplements are major factors driving the spirulina market growth.
Additionally, high penetration of spirulina in industries such as cosmetics and pharmaceutical owing to the advantageous properties such as anti-aging, anti-wrinkles and othersare bringing changes in market tends.However, low stability & poor sustainability of spirulina derived colours is expected to restrict the market growth.Moreover, growth in research & development activities followed by untapped market opportunities in developing economies are anticipated to provide numerous opportunities to the market players in the coming few years.On the basis of type, spirulina market share is segmented into Arthrospira Platensis and Arthrospira Maxima.
Arthrospira Maxima dominates the global Spirulina market and will be the dominant throughout the forecasted period.On the basis of application, the Spirulina market is categorised into Nutraceuticals, Food & Beverages, Cosmetics, Animal Feed, and Others.Food & Beverages segment is likely to develop significantly over the period of time owing to fast growing food & beverage industry.On the basis of drug formulation, the spirulina market is bifurcated into Powder, Tablet & Capsule, Liquid, and Granule & Gelling Agent.
Powder segment is expected to account for the major market share & dominate the market growth over the forecast period.North America dominates the spirulina market in terms of market size over the forecast period, owing to rising health consciousness among people.
Hansen Holding A/S, Algenol Biofuels Inc., Dongtai City Spirulina Bio-engineering Co., Ltd., Prolgae, Parry Neutraceuticals, Sensient Technologies Corporation, DDW Inc., Algatec and Naturex S.A.Browse key industry insights from the report, “Spirulina Market Size By Type (ArthrospiraPlatensis and Arthrospira Maxima) By Application (Nutraceuticals, Food & Beverages, Cosmetics, Animal Feed, and Others), By Drug Formulation (Powder, Tablet & Capsule, Liquid, and Granule & Gelling Agent)Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Russia, China, India, Japan, Australia, Indonesia, Malaysia, South Korea, Brazil, Mexico, South Africa, Saudi Arabia, UAE, Kuwait), Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020–2030” in detail along with the table of contents:Key Insights from the Spirulina Market Report:Asia Pacific is the fastest growing region in Spirulina market owing to the rising demand of spirulina from various industries such as cosmetics, food , healthcare and others and government initiatives to promote local spirulina production.The Food & Beverages segment dominates the market in terms of application and is expected to grow at a significant CAGR to maintain the lead till 2030.Some of the major players in the market are DIC Corporation, Cyanotech Corporation, Chr.
“Global Adaptive Cruise Control (ACC) Systems Market 2025” Report Provides Porters Five Forces Analysis Illustrates the Potency of Buyers & Suppliers Operating in the Industry & the Quantitative Analysis of The Global Market from 2019 to 2025 is Provided to Determine the Market Potential.
Quantitative analysis of the industry from 2014 to 2025 by Region, Type, Application.
Industrial chain,upstream and downstream situation involved in this market.
Request a sample of Adaptive Cruise Control (ACC) Systems Market report @ http://www.arcognizance.com/enquiry-sample/556644
Geographically, global Adaptive Cruise Control (ACC) Systems market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
Access this report Adaptive Cruise Control (ACC) Systems Market @ http://arcognizance.com/report/global-adaptive-cruise-control-acc-systems-market-research-report-2019-by-manufacturers-regions-types-and-applications
Your search for the best provider of Sapphire optics in Mainland China ends with UltiTech Sapphire.
Regardless of whether you are a player in the medical market or the laser market or the industrial market, you can get the Sapphire components that you require from UltiTech Sapphire.http://www.sapphire-optics.com/ultra-thin-sapphire-window-25mm-x-05mm.html
